Ser2279
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser2279  -  p300 (human)

Site Information
PVQPNPMsPQQHMLP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 486262

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 3 ) , phospho-antibody ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
fibrosarcoma ( 1 , 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
C/EBP-beta (human) ( 1 , 2 ) , HIPK2 (human) ( 2 )
Putative in vivo kinases:
ERK2 (human) ( 3 ) , HIPK2 (human) ( 2 )
Kinases, in vitro:
ERK2 (human) ( 3 )
Treatments:
celastrol ( 1 ) , EGF ( 3 ) , U0126 ( 3 )

Downstream Regulation
Effects of modification on p300:
enzymatic activity, induced ( 3 ) , molecular association, regulation ( 3 )
Effects of modification on biological processes:
transcription, altered ( 3 )

References 

1

Coulibaly A, et al. (2018) The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression. PLoS One 13, e0190934
29394256   Curated Info

2

Steinmann S, et al. (2013) Interaction and Cooperation of the CCAAT-box Enhancer-binding Protein β (C/EBPβ) with the Homeodomain-interacting Protein Kinase 2 (Hipk2). J Biol Chem 288, 22257-69
23782693   Curated Info

3

Chen YJ, Wang YN, Chang WC (2007) ERK2-mediated C-terminal serine phosphorylation of p300 is vital to the regulation of epidermal growth factor-induced keratin 16 gene expression. J Biol Chem 282, 27215-28
17623675   Curated Info